"Immutep will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti. The expected cash reach of the Company extends into early calendar year 2026."
Ann: Immutep receives Australian R&D Tax Incentive, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
-0.005(1.09%) |
Mkt cap ! $540.9M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 46.5¢ | 44.0¢ | $1.250M | 2.760M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 72517 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 32110 | 4 |
View Market Depth
| Last trade - 16.10pm 13/05/2024 (20 minute delay) ? |
|
|||||
|
Last
45.3¢ |
Change
-0.005 ( 2.60 %) |
||||
| Open | High | Low | Volume | ||
| 46.0¢ | 46.0¢ | 44.0¢ | 589940 | ||
| Last updated 15.59pm 13/05/2024 ? | |||||
| IMM (ASX) Chart |